Latest Biotech News

Page 17 of 27
Patrys Limited has launched a fully underwritten entitlement offer to raise approximately $1.77 million, aiming to accelerate development and commercial activities around its deoxymabs program.
Ada Torres
Ada Torres
23 July 2025
Amplia Therapeutics has launched a $27.5 million capital raising to advance its lead drug Narmafotinib, a promising FAK inhibitor showing superior efficacy in pancreatic cancer trials. The funds will support ongoing and new clinical studies, positioning the company for pivotal regulatory milestones.
Ada Torres
Ada Torres
23 July 2025
AdAlta Limited has prioritized two promising CAR-T cellular immunotherapy products for licensing agreements and successfully raised $1.3 million to support its strategic expansion. The company’s focused capital management and pipeline refinement signal a pivotal phase in its ‘East to West’ strategy.
Ada Torres
Ada Torres
23 July 2025
Inhalerx Limited has drawn $247,000 from a $38.5 million funding facility to advance clinical trials for its IRX-211 and IRX-616a drug candidates, reporting positive operating cash flow for the quarter ending June 2025.
Ada Torres
Ada Torres
22 July 2025
InhaleRx Limited has secured key ethics approvals and initiated manufacturing for its inhaled drug candidates targeting breakthrough cancer pain and panic disorder, supported by a $38.5 million funding facility to accelerate development.
Ada Torres
Ada Torres
22 July 2025
Prescient Therapeutics has extended the closing date of its Share Purchase Plan to July 25, 2025, responding to shareholder demand and reinforcing strong participation. The oncology-focused biotech also highlights upcoming clinical milestones and ongoing investor engagement.
Ada Torres
Ada Torres
22 July 2025
Bio-Gene Technology Limited has completed the second tranche of its share placement, securing approximately A$2.46 million and issuing unlisted options to investors and its lead manager.
Ada Torres
Ada Torres
21 July 2025
Cleo Diagnostics reports steady progress in its ovarian cancer diagnostic test development, with clinical trial recruitment on track and strategic access to major biobanks enhancing its regulatory pathway.
Ada Torres
Ada Torres
21 July 2025
Nyrada has successfully dosed and discharged the final participants in its Phase I trial of Xolatryp, reporting no adverse safety signals and setting the stage for Phase II development.
Ada Torres
Ada Torres
21 July 2025
Imugene Limited has launched a $37.5 million equity raising through a Placement and Share Purchase Plan, offering new shares and options to fund its pivotal azer-cel clinical program. The raise includes attaching and piggyback options, subject to shareholder approval, aiming to bolster the company’s immuno-oncology pipeline.
Ada Torres
Ada Torres
16 July 2025
Lumos Diagnostics has inked a landmark six-year exclusive distribution agreement with PHASE Scientific for its FebriDx® rapid diagnostic test in the US, potentially unlocking nearly half a billion Australian dollars in revenue contingent on FDA approval.
Ada Torres
Ada Torres
16 July 2025
Prescient Therapeutics has initiated its first US clinical site for the PTX-100 Phase 2a trial targeting Cutaneous T-Cell Lymphoma, marking a key milestone in expanding patient recruitment beyond Australia.
Ada Torres
Ada Torres
16 July 2025